Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
Related Content
-
Robert Molokie, MDDr. Robert Molokie is a hematologist and...
-
Doris Duke Charitable Foundation awards grant to Critical Path InstituteIn a continuing effort to spur advance...
-
Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of CareImportance: Sickle cell disease (SCD) i...
-
Jeffrey Lebensburger, MDDr. Lebensburger is a graduate of the Un...
-
Sickle Cell Disease: Racism in the American Health Care SystemWednesday, June 28 1-4 pm EDT Massachu...
-
Winthrop-University HospitalNYU Winthrop's pediatric hematologists p...
-
Diggs-Kraus Sickle Cell CenterThe Diggs-Kraus Sickle Cell Center at Re...
+myBinder